List of Excipients in Branded Drug HYDROCORTISONE ACETATE PRAMOXINE HCL

« Back to Dashboard

Generic Drugs Containing HYDROCORTISONE ACETATE PRAMOXINE HCL

Company	Ingredient	NDC	Excipient
Padagis Israel Pharmaceuticals Ltd	hydrocortisone acetate pramoxine hcl	45802-144	CETYL ALCOHOL
Padagis Israel Pharmaceuticals Ltd	hydrocortisone acetate pramoxine hcl	45802-144	ISOPROPYL PALMITATE
Padagis Israel Pharmaceuticals Ltd	hydrocortisone acetate pramoxine hcl	45802-144	POLYOXYL 40 STEARATE
Padagis Israel Pharmaceuticals Ltd	hydrocortisone acetate pramoxine hcl	45802-144	POTASSIUM SORBATE

What are the Most Frequently-Used Excipients in HYDROCORTISONE ACETATE PRAMOXINE HCL?

# Of NDCs	Excipient
3	CETYL ALCOHOL
3	ISOPROPYL PALMITATE
3	POLYOXYL 40 STEARATE
3	POTASSIUM SORBATE

Hydrocortisone Acetate and Pramoxine Hydrochloride: Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: September 24, 2026

Hydrocortisone acetate 1% and pramoxine hydrochloride 1% is a mature topical combination used for temporary relief of anorectal inflammation, itching, burning, and discomfort. The largest commercial opportunity is not new-molecule exclusivity. It is differentiated delivery: lower-irritation excipients, improved rectal retention, preservative reduction, metered dosing, foam stability, and convenient generic or private-label presentations.

The combination is a small-molecule product with limited biosimilar exposure and generally modest patent barriers. Formulation know-how, device performance, manufacturing consistency, and regulatory execution are more important than composition-of-matter patent protection.

What is hydrocortisone acetate and pramoxine hydrochloride used for?

Hydrocortisone acetate is a corticosteroid that reduces local inflammation, redness, swelling, and itching. Pramoxine hydrochloride is a local anesthetic that provides temporary relief from anorectal pain, burning, and itching.

The combination is used in products for hemorrhoids and other minor anorectal irritation. Commercial dosage forms include rectal aerosol foam, creams, ointments, lotions, and topical preparations. Product labeling generally limits duration of use and advises medical evaluation for persistent or worsening symptoms. The FDA-approved Proctofoam HC label identifies hydrocortisone acetate 1% and pramoxine hydrochloride 1% as the active ingredients in a rectal aerosol foam product.[1]

Active-ingredient characteristics relevant to excipient selection

Attribute	Hydrocortisone acetate	Pramoxine hydrochloride
Therapeutic role	Topical corticosteroid	Local anesthetic
Salt or ester	Acetate ester	Hydrochloride salt
Formulation implication	Poor aqueous solubility; suspension or cosolvent strategy may be required	More water-compatible ionic compound
Key risk	Crystallization, polymorphic behavior, dose uniformity	pH sensitivity, potential irritation, compatibility with preservatives
Primary performance target	Uniform anti-inflammatory dose and skin or mucosal deposition	Rapid and uniform local anesthetic availability
Commercial differentiation	Retention, comfort, low irritation	Fast onset, reduced stinging, consistent delivery

The two actives impose different formulation requirements. Hydrocortisone acetate tends to drive suspension stability and particle-size control. Pramoxine hydrochloride tends to drive aqueous-phase compatibility, pH selection, and preservative compatibility.

What excipients are used in hydrocortisone-pramoxine products?

The excipient system depends on the dosage form. A representative hydrocortisone acetate/pramoxine hydrochloride rectal foam contains an emulsion or dispersion base, fatty alcohols, surfactants, humectants, preservatives, water, and a propellant system.[1]

Typical functional classes include:

Excipient class	Examples	Primary function
Aqueous vehicle	Purified water	Dissolves or disperses pramoxine hydrochloride
Humectant or cosolvent	Propylene glycol, glycerin	Moisture retention and solvency
Emollient	Mineral oil, medium-chain triglycerides, fatty esters	Skin feel and barrier support
Structuring agent	Cetyl alcohol, stearyl alcohol, glyceryl stearate	Viscosity, emulsion structure, foam body
Surfactant	Polysorbates, nonionic emulsifiers	Emulsion stability and wetting
Suspending agent	Carbomer, cellulose derivatives, colloidal systems	Hydrocortisone acetate uniformity
Preservative	Parabens, phenoxyethanol, organic acids	Microbial control
Buffer or pH modifier	Citric acid, sodium citrate, phosphate salts	pH control and active stability
Propellant	Hydrocarbon or alternative propellant	Foam generation and product evacuation
Chelating agent	Disodium EDTA	Metal-ion control and preservative support

The FDA Inactive Ingredient Database can support excipient selection by identifying prior use in approved dosage forms and routes, but database presence does not establish suitability for every concentration or product design.[2]

Which excipient strategy is strongest for a new commercial product?

A robust strategy is to separate the product into three design targets: active-ingredient compatibility, patient comfort, and delivery performance.

Low-irritation aqueous cream

A low-irritation cream can use a nonionic emulsion system with controlled pH, a reduced preservative load, and a finely milled hydrocortisone acetate suspension. This approach is suitable for tube or pump packaging and is easier to manufacture than a pressurized foam.

Commercial advantages include:

• Lower packaging complexity
• Easier filling and scale-up
• Broad private-label potential
• Compatibility with pharmacy and retail channels
• Opportunity for preservative-reduced or fragrance-free positioning

The principal technical risk is dose uniformity during storage and use. Hydrocortisone acetate must remain evenly dispersed, and the product must not separate under temperature cycling.

Rectal foam

Foam remains the strongest dosage-form differentiation opportunity. It can spread over a broader mucosal area, reduce the need for manual application, and provide a distinctive patient experience.

A foam design must control:

• Foam density
• Collapse time
• Extrusion force
• Valve and actuator performance
• Active-ingredient content uniformity
• Propellant compatibility
• Microbial control
• Residual product in the canister
• Stability under elevated temperature and humidity

A modern product could use a bag-on-valve system or another low-residue delivery architecture. Such systems may support propellant reduction, cleaner dispensing, and improved dose consistency. The commercial benefit must be demonstrated through usability and stability data because packaging and device changes can create regulatory and manufacturing burdens.

Ointment or water-in-oil system

An ointment can improve occlusivity and persistence on external hemorrhoidal tissue. It is less attractive for internal rectal use if the product is greasy, difficult to clean, or poorly tolerated.

This format is most suitable for:

• External hemorrhoids
• Nighttime use
• Barrier protection
• Dry or fissured perianal tissue
• Combination products with a protectant

The primary opportunity is bundling hydrocortisone-pramoxine with a barrier or skin-protectant positioning, subject to applicable FDA labeling and monograph requirements.

What formulations are protected by patents?

The commercial formulation is more likely to be protected by formulation know-how, process controls, trademarks, and device configuration than by a live composition-of-matter patent.

The relevant patent categories are:

1. Emulsion or suspension systems that maintain hydrocortisone acetate uniformity.
2. Foam systems with defined density, collapse behavior, or propellant composition.
3. Applicators, valves, metered-dose systems, and bag-on-valve packaging.
4. Preservative-free or low-preservative compositions.
5. Manufacturing processes that control particle size, temperature, mixing, or filling.
6. Combination products with defined dosing regimens or treatment methods.

A patent claim directed only to the basic combination of hydrocortisone acetate and pramoxine hydrochloride is likely to face substantial prior-art pressure because both actives and the therapeutic use are longstanding. Formulation claims require credible performance differentiation, such as improved stability, reduced irritation, enhanced retention, or reproducible foam delivery.

Patentability is stronger where the applicant can show a technical effect tied to a narrow excipient ratio or manufacturing parameter. Broad claims covering conventional creams, suspensions, or foams are more vulnerable to obviousness and anticipation challenges.

When does hydrocortisone-pramoxine lose exclusivity?

The active ingredients are mature and do not carry the exclusivity profile associated with recently approved small molecules or biologics. The key commercial distinction is between regulatory exclusivity for a specific NDA product and market exclusivity for the active ingredients.

Exclusivity category	Relevance to this combination
Composition-of-matter patent	Generally limited commercial relevance because the actives are old
New-drug exclusivity	Depends on the specific NDA and approval history
Formulation patent	May apply to a particular foam, cream, device, or manufacturing process
Method-of-use patent	Possible but difficult to sustain for established anorectal uses
Orphan exclusivity	Not applicable to the conventional indication
Biosimilar exclusivity	Not applicable; this is a small-molecule product
OTC monograph pathway	May apply to certain active ingredients and indications, but the complete combination and dosage form must be assessed separately
ANDA pathway	May be available where an approved reference product and abbreviated pathway are applicable

A precise patent-expiration or Orange Book analysis must be tied to a specific reference product, NDA, dosage form, and jurisdiction. The combination name alone does not identify one definitive patent estate.

What is the FDA regulatory status of hydrocortisone acetate and pramoxine hydrochloride?

Products containing the two actives may occupy different regulatory positions depending on formulation, indication, concentration, route, and labeling.

The relevant FDA pathways are:

• Prescription NDA or 505(b)(2) approval for a specific combination product
• ANDA approval for a therapeutically equivalent generic, where applicable
• OTC monograph compliance for eligible active ingredients and indications
• An FDA review pathway for products that combine actives, dosage forms, or claims outside established monograph conditions

Hydrocortisone and pramoxine each have established topical and anorectal uses, but that does not automatically place every combination product within an OTC monograph. The sponsor must assess the exact active concentrations, dosage form, route, labeling, manufacturing controls, and permitted claims under applicable FDA regulations.[3]

For a prescription foam, regulatory risk is concentrated in:

• Demonstrating sameness or equivalence to the reference product
• Device and container-closure performance
• In-use stability
• Dose delivery
• Microbial limits and preservative effectiveness
• Human-factors performance for the applicator

What is the Orange Book status of hydrocortisone-pramoxine products?

The Orange Book lists approved drug products and, where applicable, patent and exclusivity information. A search must be conducted under the specific proprietary name, active ingredients, dosage form, applicant, and NDA number.[4]

An Orange Book review should verify:

• Whether the reference product has an active listing
• Whether patents are listed for the product
• Whether pediatric exclusivity affects the listed dates
• Whether an ANDA reference product is available
• Whether a Paragraph IV filing could target listed patents
• Whether the proposed generic must use a different formulation or route

For an old topical combination, the commercial barrier may arise from product complexity rather than an extensive Orange Book patent listing. A generic sponsor can still face substantial development work if the product is a foam, suspension, or device-linked dosage form.

Which companies are challenging hydrocortisone-pramoxine products?

Competition is likely to come from several groups:

• Generic dermatology and gastrointestinal manufacturers
• Specialty topical manufacturers
• Contract development and manufacturing organizations
• Private-label pharmacy suppliers
• OTC hemorrhoid brands using hydrocortisone, pramoxine, phenylephrine, protectants, or local anesthetics
• Retail brands selling creams, ointments, wipes, suppositories, and sprays

The competitive set is broader than products containing the exact combination. Patients and prescribers may substitute among hydrocortisone-only products, pramoxine-only products, lidocaine products, barrier creams, witch hazel products, and combination hemorrhoid therapies.

A company entering the market should compete on dosage-form performance and patient convenience rather than rely on the ingredient names alone.

What generic entry risks exist?

Generic entry risk is high for a simple cream and moderate for a foam or device-dependent product.

Product type	Generic development difficulty	Main barrier
Conventional cream	Low	Formulation sameness and stability
Ointment	Low to moderate	Rheology, spreadability, active uniformity
Lotion	Moderate	Suspension stability and microbial control
Rectal foam	Moderate to high	Foam performance, device, propellant, dose delivery
Bag-on-valve foam	Moderate to high	Container-closure and actuator equivalence
Preservative-free single-use product	Moderate	Packaging cost, microbial assurance, stability

A Paragraph IV strategy is most relevant where the reference product has listed patents. If the patent estate is weak or expired, market entry may depend on ANDA approval timing and commercial scale rather than litigation.

Patent litigation risk is generally lower for mature topical combinations than for patented oral small molecules, but device and formulation patents can still create targeted disputes. Settlement agreements should be reviewed for launch dates, royalty obligations, authorized-generic rights, and restrictions on formulation changes.

How strong is the patent estate for this combination?

The estate is likely weak at the active-ingredient level and potentially stronger at the product level.

Stronger protection areas

• Specific foam architecture
• Metered or controlled-dose applicators
• Novel preservative-free systems
• Narrow excipient ranges linked to superior stability
• Manufacturing controls that produce a measurable performance benefit
• Packaging that reduces residual drug or improves dose reproducibility

Weaker protection areas

• Hydrocortisone acetate alone
• Pramoxine hydrochloride alone
• Generic topical creams
• Conventional fatty alcohol emulsions
• Broad claims covering treatment of hemorrhoids with the known actives
• Routine substitution of one conventional preservative or surfactant for another

The most defensible IP strategy would combine composition claims, process claims, container-closure claims, and trade-secret controls for particle-size distribution, mixing order, temperature profile, and filling parameters.

What commercial opportunities exist?

The highest-value opportunities are differentiated generic and branded-generic products.

Preservative-reduced or preservative-free product

A preservative-reduced cream or single-use presentation could target patients with sensitivity to parabens or repeated-use irritation. The product would require rigorous microbial-risk management and packaging validation.

Premium rectal foam

A modern foam could command a premium if it improves application comfort, reduces mess, and provides consistent dose delivery. The commercial case is strongest where the product offers a measurable usability advantage over legacy aerosol foam.

Pharmacy and private-label supply

A stable cream or ointment has a relatively low development barrier and can support private-label programs. Contract manufacturing, bulk supply, and regional licensing may be more attractive than building a consumer brand.

Combination with barrier protection

A hydrocortisone-pramoxine product combined with a skin protectant may address both inflammation and friction-related discomfort. The regulatory strategy must avoid unsupported therapeutic claims and ensure compatibility among the active ingredients and protectant.

Geographic expansion

The same active combination can be adapted for markets where hemorrhoid products are sold through prescription, pharmacy, or OTC channels. Regulatory classification, permitted concentrations, labeling language, applicator requirements, and excipient restrictions vary by country.

How does this product compare with competing hemorrhoid therapies?

Product category	Main benefit	Main limitation	Commercial threat
Hydrocortisone alone	Anti-inflammatory effect	No local anesthetic	High
Pramoxine alone	Itch and pain relief	Limited anti-inflammatory activity	High
Lidocaine products	Familiar anesthetic	Irritation or systemic exposure concerns if misused	Moderate to high
Barrier protectants	Physical protection	No corticosteroid effect	High
Vasoconstrictor products	Symptom relief	Cardiovascular and labeling considerations	Moderate
Suppositories	Internal delivery	Less convenient and limited external coverage	Moderate
Foam products	Broad application and low residue	Device and manufacturing complexity	Direct competitor

Hydrocortisone acetate plus pramoxine hydrochloride has a rational dual mechanism, but differentiation depends on delivery performance. The active ingredients alone are unlikely to support a durable premium.

Key Takeaways

• Hydrocortisone acetate and pramoxine hydrochloride is a mature small-molecule combination with low biosimilar risk.
• The main commercial opportunity is in creams, foams, ointments, and private-label products with better tolerability or delivery.
• Hydrocortisone acetate drives suspension stability, particle-size control, and dose uniformity.
• Pramoxine hydrochloride drives aqueous compatibility, pH selection, and preservative assessment.
• Foam, metered dosing, bag-on-valve packaging, and preservative-reduced systems offer the strongest differentiation.
• The active-ingredient patent estate is likely weak; formulation, device, process, and trade-secret protection are more relevant.
• Generic entry risk is low for conventional creams and higher for rectal foams or device-dependent products.
• FDA status and Orange Book conclusions must be made for a specific product, NDA, dosage form, and jurisdiction.
• Manufacturing consistency and patient usability are likely to determine commercial success more than active-ingredient exclusivity.

FAQs

Is hydrocortisone acetate the same as hydrocortisone base?

No. Hydrocortisone acetate is an ester with different physicochemical properties, including lower water solubility. The distinction affects suspension design, dissolution, release, and dose uniformity.

Can pramoxine hydrochloride and hydrocortisone acetate be formulated in a water-based cream?

Yes. Pramoxine hydrochloride can be incorporated into the aqueous phase, while hydrocortisone acetate generally requires dispersion, suspension, or a suitable cosolvent and emulsion strategy.

Is a hydrocortisone-pramoxine foam difficult to manufacture?

It is more complex than a conventional cream because foam density, collapse, propellant behavior, valve delivery, active uniformity, and residual product must remain within specification throughout shelf life.

Does this combination have biosimilar competition?

No. Hydrocortisone acetate and pramoxine hydrochloride are small-molecule active ingredients. Competitive products would generally be generics, authorized generics, branded generics, or OTC alternatives.

Can a new excipient combination receive patent protection?

Potentially, but protection is strongest when a narrow excipient system produces a documented technical effect, such as improved stability, reduced irritation, enhanced retention, or more consistent foam delivery.

References

1. U.S. Food and Drug Administration. (n.d.). Proctofoam HC hydrocortisone acetate and pramoxine hydrochloride aerosol, foam: Prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Parts 346 and 348: Anorectal drug products and external analgesic drug products. https://www.ecfr.gov/
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files or the current FDA Orange Book database.